Skip to Content
  • Ezetimibe In the Marketplace

    Several years ago, the Schering-Plough cholesterol absorption inhibitor (Zetia, ezetimibe) and its combination pill with simvastatin (Vytorin) were the subject… Read More
  • The Nasty Side of HDL

    A recurring theme here when I talk about cardiovascular drug discovery is how poorly we understand human lipidology. Surprise after surprise has followed on eff… Read More
  • Merck Pulls One Out

    Merck’s vorapaxar, a thrombin antagonist that many had thought might never make it, has received a positive FDA advisory committee vote. I’m glad to… Read More
  • Nasty Odor as a Drug Side Effect

    If you read the publications on the GSK compound (darapladib) that just failed in Phase III, you may notice something odd. These mention “odor” as a… Read More
  • Dietary Fat and Heart Disease

    Here’s a provocative article at the British Medical Journal on cardiovascular outcomes and diet. Now, I free admit that the BMJ has a tendency towards con… Read More
  • The First PCSK9 Phase III

    Some long-awaited clinical data has appeared in the cardiovascular area: Sanofi and Regeneron have the first Phase III numbers for their PCSK9-blocking antibody… Read More
  • Clinical Trial Fraud Uncovered

    Hmmm. This article from Bloomberg says that the BMS/Pfizer anticoagulant Eliquis (apixaban), a Factor Xa inhibitor approved late last year by the FDA, was delay… Read More
  • An Anticoagulant Antidote

    Here’s a drug-discovery problem that you don’t often have to think about. The anticoagulant field is a huge one, with Plavix, warfarin, and plenty o… Read More
Page 4 of 17« First...23456...10...Last »